Lempo Therapeutics

Gene Editing for Treatment of Chronic Disease

Health Tech & Life Sciences
Active
Pre-Funding Binyamina-Giv'at Ada Founded 2017
Total raised
Stage
Pre-Funding
Founded
2017
Headcount
3
HQ
Binyamina-Giv'at Ada
Sector
Health Tech & Life Sciences

About

Lempo Therapeutics is a preclinical biotech company that uses gene editing to modify the immune system for attenuating severe chronic diseases. The companys novel, patented treatment uses an ex vivo stem cell gene-editing technique to minimize the collateral damage caused by immune system activity, thereby significantly mitigating disease progression. Lempos initial focus is on treating pulmonary arterial hypertension (PAH), a rare and devastating cardiovascular disease that leads to heart failure and death if left untreated. The companys concept has already been proven effective in animal models for the treatment of Alzheimers disease, multiple sclerosis, cardiovascular diseases, and more.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

treatmentscardiovascularmultiple-sclerosisalzheimers-diseasechronic-diseasehospitalsbiotechnologypharmaceuticalsgene-editingimmunologystem-cellsbioconvergence